Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370911 · ClinicalTrials.gov registry record · Phase 1
Effects of Repeated Psilocybin Dosing in OCD
A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05370911: Active Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Yale University.
NCT05370911 is a Phase 1 study of Obsessive - Compulsive Disorder that is active but no longer recruiting, run by Yale University. The registered enrollment target is 30 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370911, a Phase 1 study of Obsessive - Compulsive Disorder, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.
Primary Outcome
Clinician-administered assessment of severity of OCD symptoms over the past seven days. The most prominent obsessions and compulsions are rated on the Severity Scale from 0 to 4. Total Y-BOCS-II scores range from 0 to 40, with higher scores indicating greater severity of OCD symptoms.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (2)
Connecticut
- Enact Research Collaborative (40 Temple St, 4th Floor) - New Haven
- Yale Program for Psychedelic Research - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-20 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What the registry record for NCT05370911 still lists
NCT05370911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05370911 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05370911 about?
NCT05370911 is a clinical study titled "Effects of Repeated Psilocybin Dosing in OCD". This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects o...
What is the current status of trial NCT05370911?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-20. Estimated completion is 2027-07.
What conditions does trial NCT05370911 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT05370911?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05370911?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370911 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05370911's enrollment target sits among peer trials
30 57th of 84 higher than 21 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
RECRUITING · Phase 1
-
Pilot Study of RR-HNK in OCD
RECRUITING · Phase 1
-
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
RECRUITING · Phase 1
-
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 1
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI